Field Trip Announces First Dosings in Phase I Clinical Study of FT-104

- First Dosings completed in Australia

- Provides Update on Pending Spin-Out and Renaming to Reunion Neurosciences

- Announces 5:1 Share Consolidation Ratio

Read more at globenewswire.com